Radiofrequency Ablation of Lung Tumors
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 60
- Registration Number
- NCT00180856
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Institut Bergonié, Bordeaux, France
Clinical Utility of the Alaris MidLatencyAuditoryEvoked Potentials Monitor to Titrate the Anesthetic-Hypnotic Component of Anesthesia
Phase 3
Suspended
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 128
- Registration Number
- NCT00181051
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 226
- Registration Number
- NCT00180908
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Phase 2
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 30
- Registration Number
- NCT00180921
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 100
- Registration Number
- NCT00181012
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Phase 2
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 71
- Registration Number
- NCT00180791
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery
Phase 3
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT00181038
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 420
- Registration Number
- NCT00180999
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 2
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT00162669
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 120
- Registration Number
- NCT00162708
- Locations
- 🇫🇷
Centre Alexis Vautrin, Nancy, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Institut Gustave Roussy, Villejuif, France
© Copyright 2024. All Rights Reserved by MedPath